'You are not the drug sponsor': FDA declines petition to anoint Cassava's drug as 'breakthrough'
A citizen asked the FDA last October to immediately give Cassava Sciences’ Alzheimer’s drug candidate simufilam the coveted breakthrough therapy tag, which shortens the timeframe for reviewing investigational medicines.
But the FDA said no this week, saying only drug sponsors can make that request. The denial was sent to Paul Efron on Feb. 28. It is unclear Efron’s reasoning for filing the petition and whether the citizen has a connection to the drug candidate. A Cassava executive did not immediately reply to an Endpoints News email and phone call.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.